223 related articles for article (PubMed ID: 25709561)
1. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.
Kmeid J; Kanafani ZA
Core Evid; 2015; 10():39-47. PubMed ID: 25709561
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
3. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.
Mitra S; Saeed U; Havlichek DH; Stein GE
Infect Drug Resist; 2015; 8():189-97. PubMed ID: 26185459
[TBL] [Abstract][Full Text] [Related]
4. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
5. Oritavancin: an investigational lipoglycopeptide antibiotic.
Karaoui LR; El-Lababidi R; Chahine EB
Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
7. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
8. Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
[TBL] [Abstract][Full Text] [Related]
10. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Bouza E; Burillo A
Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
13. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
[TBL] [Abstract][Full Text] [Related]
14. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
Henson KE; Levine MT; Wong EA; Levine DP
Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
[TBL] [Abstract][Full Text] [Related]
15. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
16. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
17. Oritavancin: A Long-Half-Life Lipoglycopeptide.
Saravolatz LD; Stein GE
Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
[TBL] [Abstract][Full Text] [Related]
18. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Crandon J; Nicolau DP
Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of oritavancin and related glycopeptide antibiotics.
Allen NE; Nicas TI
FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
[TBL] [Abstract][Full Text] [Related]
20. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
